Evidence map›Paper›PMID 37608789›Full record

ArticleFrontiers in endocrinology2023

Editorial: FGF21 as a therapeutic target for obesity and insulin resistance: from rodent models to humans.

A L De Sousa-Coelho, R Rodriguez-Rodriguez, S Softic, J W Jonker, J Relat

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

A L De Sousa-CoelhoEscola Superior de Saúde (ESS), Universidade do Algarve (UAlg), Faro, Portugal.
R Rodriguez-RodriguezBasic Sciences Department, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain.
S SofticDepartment of Pediatrics, Division of Pediatric Gastroenterology, Kentucky Children's Hospital, and Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, United States.
J W JonkerDepartment of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
J RelatCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Insulin ResistanceAnimalsFibroblast Growth FactorsHumansObesityRodentiafibroblast growth factor 21Fibroblast Growth Factorsbeta-KlothoFGF21 (fibroblast growth factor 21)insulin resistancemetabolismobesity

Identifiers

PMID37608789
PMCPMC10441540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.